ERBB2 and invasive breast carcinoma: Patient outcome of these basic intrinsic BrCa subtypes has been generally established [21] with median overall survivals of approximately 12, 20 and 56 months, respectively for patients with TNBC, Luminal and HER2 types [22,23,24].